346 related articles for article (PubMed ID: 22903299)
21. Inhibition of cancer cell growth by ruthenium(II) arene complexes.
Morris RE; Aird RE; Murdoch Pdel S; Chen H; Cummings J; Hughes ND; Parsons S; Parkin A; Boyd G; Jodrell DI; Sadler PJ
J Med Chem; 2001 Oct; 44(22):3616-21. PubMed ID: 11606126
[TBL] [Abstract][Full Text] [Related]
22. Ruthenation of duplex and single-stranded d(CGGCCG) by organometallic anticancer complexes.
Liu HK; Wang F; Parkinson JA; Bella J; Sadler PJ
Chemistry; 2006 Aug; 12(23):6151-65. PubMed ID: 16807967
[TBL] [Abstract][Full Text] [Related]
23. Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes.
Fernández R; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Chemistry; 2004 Oct; 10(20):5173-9. PubMed ID: 15372674
[TBL] [Abstract][Full Text] [Related]
24. Heteroleptic arene ruthenium complexes based on meso-substituted dipyrrins: synthesis, structure, reactivity, and electrochemical studies.
Yadav M; Singh AK; Maiti B; Pandey DS
Inorg Chem; 2009 Aug; 48(16):7593-603. PubMed ID: 19610658
[TBL] [Abstract][Full Text] [Related]
25. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
[TBL] [Abstract][Full Text] [Related]
26. Energetics, conformation, and recognition of DNA duplexes modified by monodentate Ru(II) complexes containing terphenyl arenes.
Novakova O; Malina J; Suchankova T; Kasparkova J; Bugarcic T; Sadler PJ; Brabec V
Chemistry; 2010 May; 16(19):5744-54. PubMed ID: 20376825
[TBL] [Abstract][Full Text] [Related]
27. Microwave-assisted synthesis of arene ruthenium(II) complexes [(η⁶-RC₆H₅)Ru(m-MOPIP)Cl]Cl (R = -H and -CH₃) as groove binder to c-myc G4 DNA.
Wu Q; Chen T; Zhang Z; Liao S; Wu X; Wu J; Mei W; Chen Y; Wu W; Zeng L; Zheng W
Dalton Trans; 2014 Jun; 43(24):9216-25. PubMed ID: 24818221
[TBL] [Abstract][Full Text] [Related]
28. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
[TBL] [Abstract][Full Text] [Related]
29. New ruthenium(II) arene complexes of anthracenyl-appended diazacycloalkanes: effect of ligand intercalation and hydrophobicity on DNA and protein binding and cleavage and cytotoxicity.
Ganeshpandian M; Loganathan R; Suresh E; Riyasdeen A; Akbarsha MA; Palaniandavar M
Dalton Trans; 2014 Jan; 43(3):1203-19. PubMed ID: 24177707
[TBL] [Abstract][Full Text] [Related]
30. Selenoquinones stabilized by ruthenium(II) arene complexes: synthesis, structure, and cytotoxicity.
Dubarle-Offner J; Clavel CM; Gontard G; Dyson PJ; Amouri H
Chemistry; 2014 May; 20(19):5795-801. PubMed ID: 24668791
[TBL] [Abstract][Full Text] [Related]
31. 1-(2-Picolyl)-substituted 1,2,3-triazole as novel chelating ligand for the preparation of ruthenium complexes with potential anticancer activity.
Bratsos I; Urankar D; Zangrando E; Genova-Kalou P; Košmrlj J; Alessio E; Turel I
Dalton Trans; 2011 May; 40(19):5188-99. PubMed ID: 21465046
[TBL] [Abstract][Full Text] [Related]
32. Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms.
Vock CA; Ang WH; Scolaro C; Phillips AD; Lagopoulos L; Juillerat-Jeanneret L; Sava G; Scopelliti R; Dyson PJ
J Med Chem; 2007 May; 50(9):2166-75. PubMed ID: 17419606
[TBL] [Abstract][Full Text] [Related]
33. Effect of substitution and planarity of the ligand on DNA/BSA interaction, free radical scavenging and cytotoxicity of diamagnetic Ni(II) complexes: a systematic investigation.
Sathyadevi P; Krishnamoorthy P; Butorac RR; Cowley AH; Bhuvanesh NS; Dharmaraj N
Dalton Trans; 2011 Oct; 40(38):9690-702. PubMed ID: 21858314
[TBL] [Abstract][Full Text] [Related]
34. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
35. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.
Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F
Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875
[TBL] [Abstract][Full Text] [Related]
36. Selective, cytotoxic organoruthenium(II) full-sandwich complexes: a structural, computational and in vitro biological study.
Loughrey BT; Cunning BV; Healy PC; Brown CL; Parsons PG; Williams ML
Chem Asian J; 2012 Jan; 7(1):112-21. PubMed ID: 22095971
[TBL] [Abstract][Full Text] [Related]
37. Half-sandwich organometallic Ru and Rh complexes of (N,N) donor compounds: effect of ligand methylation on solution speciation and anticancer activity.
Mészáros JP; Pape VFS; Szakács G; Németi G; Dénes M; Holczbauer T; May NV; Enyedy ÉA
Dalton Trans; 2021 Jun; 50(23):8218-8231. PubMed ID: 34032247
[TBL] [Abstract][Full Text] [Related]
38. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
[TBL] [Abstract][Full Text] [Related]
39. Ruthenium(II/III)-based compounds with encouraging antiproliferative activity against non-small-cell lung cancer.
Nagy EM; Pettenuzzo A; Boscutti G; Marchiò L; Dalla Via L; Fregona D
Chemistry; 2012 Nov; 18(45):14464-72. PubMed ID: 23012112
[TBL] [Abstract][Full Text] [Related]
40. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells.
Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V
Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
